IAS 38 requires entities to distinguish between research costs (expensed) and development costs (capitalised), with no bright‑line transition point and judgement applied project by project. In practice, demonstrating technical feasibility is often the most challenging criterion, meaning many pharma entities expense costs until late-stage milestones, with regulatory approval commonly viewed as a strong indicator of meeting the criteria for capitalisation. However, regulatory approval is not explicitly required under IAS 38, and earlier capitalisation may be appropriate where all six criteria are met.
Introduction
Accounting for research and development (R&D) in entities such as those in the pharmaceuticals sector may materially affect reported performance and comparability. Under IFRS, research is expensed as incurred, while development must be capitalised on the balance sheet when all six recognition criteria required by IAS 38 Intangible Assets are met.
When does “research” become “development”?
Key challenges for pharma companies (IFRS)
Determining when the IAS 38 criteria are met is judgmental because feasibility and economic benefits are uncertain prior to late development. Entities often expense a large proportion of R&D until close to filing/approval, and these affect profit volatility and peer comparability.
Only costs directly attributable to producing, creating and preparing the asset for its intended use, including directly attributable overheads, can be capitalised once recognition criteria are met (e.g., certain clinical / production design costs). Promotional, market access, post-approval surveillance, and non-directly attributable overheads are expensed.
IAS 38 does not link capitalisation to specific clinical trial phases; instead, recognition is driven by the six criteria, regardless of whether a project is in Phase I, II or III. In practice, Phase I–II costs are typically expensed due to high technical and regulatory uncertainty; while many entities continue to expense Phase III costs, more judgement is involved as to whether those costs should be expensed or capitalised. Although not required by IAS 38, filing or marketing authorisation is often viewed in practice as strong evidence that the capitalisation criteria are met, with earlier capitalisation only where feasibility, resources and future economic benefits can be robustly demonstrated.
Once development costs are capitalised as intangible assets under IAS 38, they are subject to the requirements of IAS 36 Impairment of Assets.
These assets are not amortised until they are available for use (e.g. post-approval and commercial launch). Until then, they must be tested for impairment annually, or sooner if indicators arise. Common triggers in the pharma sector include adverse clinical or regulatory outcomes, competitor launches, or changes in market expectations.
Once the asset becomes available for use, amortisation begins over its estimated useful life, and impairment testing continues if indicators emerge.
Treatment of acquired in-process research and development (IPR&D)
IPR&D may be acquired rather than developed internally. When acquired in a business combination, IPR&D are recognised separately from goodwill upon acquisition as identifiable intangible assets and are measured at fair value. IPR&D acquired outside a business combination will generally be recognised as an intangible asset as well.
Until the underlying asset is available for use, acquired IPR&D is generally treated as having an indefinite life, and tested annually for impairment (and whenever indicators arise) under IAS 36.
Any subsequent R&D expenditure on the acquired project is expensed until it meets the six criteria under IAS 38 for capitalising development costs.
Key takeaways
IPR&D may be acquired rather than developed internally. When acquired in a business combination, IPR&D are recognised separately from goodwill upon acquisition as identifiable intangible assets and are measured at fair value. IPR&D acquired outside a business combination will generally be recognised as an intangible asset as well.
Until the underlying asset is available for use, acquired IPR&D is generally treated as having an indefinite life, and tested annually for impairment (and whenever indicators arise) under IAS 36.
Any subsequent R&D expenditure on the acquired project is expensed until it meets the six criteria under IAS 38 for capitalising development costs.
How can we help?
Our Accounting Advisory Services team supports organisations through complex accounting and reporting challenges, drawing on deep technical expertise and strong pharmaceutical sector specialism.
Please get in touch to discuss how our specialists can help you navigate your specific circumstances.
Our accounting and finance insights
Something went wrong
Oops!! Something went wrong, please try again
Get in touch
Discover why organisations across the UK trust KPMG to make the difference and how we can help you to do the same.